PFS
MYGN icon

Prospera Financial Services’s Myriad Genetics MYGN Stock Holding History

Prospera Financial Services’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$5K – 2242
2022
Q1 		$5K Buy
+200
New +$5.12K ﹤0.01% 2270
2020
Q4 		– Sell
-200
Closed -$3K – 1241
2020
Q3 		$3K Buy
+200
New +$2.53K ﹤0.01% 1400

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prospera Financial Services's MYGN Position: Q2 2022 in Review

Prospera Financial Services sold out of Myriad Genetics (MYGN) in Q2 2022, closing a stake of 200 shares — an estimated $5K sold.

Prospera Financial Services first reported a position in MYGN in Q3 2020 and held it in 2 quarters. The position peaked at $5K in Q1 2022. 198 funds tracked by Wall St. Rank hold MYGN as of Q2 2022.

  • Prospera Financial Services reported no remaining Myriad Genetics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 200 Myriad Genetics shares in Q2 2022, an estimated $5K.
  • Prospera Financial Services first reported a position in Myriad Genetics in Q3 2020 and held it in 2 quarters.
  • Prospera Financial Services's Myriad Genetics position peaked at $5K in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.